RxDoctor Payments DataLook up a doctor →

Ramesh Singa, MD

Pain Medicine · Austin, TXNPI 1184981805

Payments from drug & device makers

$34,126in general payments, 2019–2025

Across 1,082 payments — averaging $31.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$9K
  • Scilex Pharmaceuticals Inc.$5K
  • Omnia Medical, LLC$3K
  • Relievant Medsystems, Inc.$2K
  • Medtronic$2K
  • Boston Scientific$2K
  • plus $11K from 45 others

What the payments were for

  • Consulting fees$3,75011%
  • Speaking & faculty fees$4,80014%
  • Travel & lodging$2,7128%
  • Food & beverage$22,86467%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,126 in reported general payments places this provider in the 90th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$203,852
Medicare patients
371
Services billed
2,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate40$19,059
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen507$13,405
ZtlidoLidocaine14$7,665
Fentanyl54$6,973
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen165$4,848
Gabapentin85$2,016
Pregabalin56$1,885
Diclofenac Sodium68$1,800
Methocarbamol35$1,446
Etodolac33$1,295
Oxycodone Hcl90$989
Morphine Sulfate ErMorphine Sulfate41$775
Celecoxib22$513
Morphine Sulfate20$419
Tizanidine Hcl15$416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$965$19,05940 claims
Scilex Pharmaceuticals Inc.Ztlido$4,564$7,66514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 pain medicine providers in Texas.

Other pain medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →